Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evoke Pharma IncEVOK · Entity 71094 | Director · CEO | February 08, 2023 | February 10, 2023 |
| Viridian Therapeutics, Inc.\DESGNL · Entity 4316 | Director | February 08, 2017 | February 08, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evoke Pharma Inc
Report date February 08, 2023 · Filed February 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.01 · Expires 2033-02-07 | Direct | 30,000 |
Reported balance
After 2023-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-08 · Grant · Acquired 30,000 · Balance 30,000 F1: The option shall vest at the rate of 1/48th of the original number of shares on each monthly anniversary of January 1, 2023, subject to the reporting person's continuous service to the issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest at the rate of 1/48th of the original number of shares on each monthly anniversary of January 1, 2023, subject to the reporting person's continuous service to the issuer on each such vesting date.
Viridian Therapeutics, Inc.\DE
Report date February 08, 2017 · Filed February 08, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,899 |
Reported balance
After 2017-02-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-02-08 · Exercise / conversion · Acquired 1,200 · Balance 1,899 F1: On November 4, 2016, the issuer effected a one-for-15 reverse split of its Common Stock (the "Reverse Split"), and the number of securities and/or the exercise price reported reflect the Reverse Split. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.65 · Expires 2026-06-15 | Direct | 0 |
Reported balance
After 2017-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-08 · Exercise / conversion · Disposed 1,200 · Balance 0 F1: On November 4, 2016, the issuer effected a one-for-15 reverse split of its Common Stock (the "Reverse Split"), and the number of securities and/or the exercise price reported reflect the Reverse Split. F2: The option initially vested and became exercisable in twelve equal monthly installments beginning on June 30, 2016 and ending on May 31, 2017. However, upon approval of the issuer's board of directors, vesting was accelerated and the option became fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 4, 2016, the issuer effected a one-for-15 reverse split of its Common Stock (the "Reverse Split"), and the number of securities and/or the exercise price reported reflect the Reverse Split.
F2: The option initially vested and became exercisable in twelve equal monthly installments beginning on June 30, 2016 and ending on May 31, 2017. However, upon approval of the issuer's board of directors, vesting was accelerated and the option became fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2023 Filed Feb 10, 2023 16:13 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001209191-23-008336 · doc4.xml · derivative · entry 1 Gonyer David A · CIK 0001578768 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-02-07 F1 · derivative.exercise_date: The option shall vest at the rate of 1/48th of the original number of shares on each monthly anniversary of January 1, 2023, subject to the reporting person's continuous service to the issuer on each such vesting date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 17:26 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001209191-22-007266 · doc4.xml · derivative · entry 1 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: The option shall vest at the rate of 1/48th of the original number of shares on each monthly anniversary of January 1, 2022, subject to the reporting person's continuous service to the issuer on each such vesting date. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 16:13 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 415,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001209191-21-006081 · doc4.xml · derivative · entry 1 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,000 Underlying: Common Stock · 415,000 shares Expires 2031-01-26 F1 · derivative.exercise_date: The option shall vest at the rate of 1/48th of the original number of shares on each monthly anniversary of January 1, 2021, subject to the reporting person's continuous service to the issuer on each such vesting date. Read SEC document |
| December 14, 2020 Filed Dec 14, 2020 20:58 UTC | Evoke Pharma Inc EVOK · Entity 71094 | SaleCommon Stock | 23,954 | $2.94 | $70,424.76 |
DisclosureSEC source: 0001209191-20-063366 · doc4.xml · nonDerivative · entry 2 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,782 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.93 to $2.97. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 20:58 UTC | Evoke Pharma Inc EVOK · Entity 71094 | SaleCommon Stock | 48,046 | $2.90 | $139,333.40 |
DisclosureSEC source: 0001209191-20-063366 · doc4.xml · nonDerivative · entry 1 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,736 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $2.93. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 20:43 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Exercise / conversionStock Option (Right to Buy) · Derivative | 72,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001209191-20-063099 · doc4.xml · derivative · entry 2 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,000 shares Expires 2021-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These options were scheduled to expire on February 8, 2021. F2 · derivative.exercise_date: These options were fully vested as of February 9, 2015. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 20:43 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Exercise / conversionCommon Stock | 72,000 | $0.40 | $28,800.00 |
DisclosureSEC source: 0001209191-20-063099 · doc4.xml · nonDerivative · entry 1 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 08:30 UTC | Evoke Pharma Inc EVOK · Entity 71094 | OtherCommon Stock | 20,238 | $1.05 | $21,249.90 |
DisclosureSEC source: 0001209191-20-049016 · doc4.xml · nonDerivative · entry 1 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,782 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 20:25 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-20-015796 · doc4.xml · derivative · entry 1 Gonyer David A · CIK 0001578768 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: One-half of the stock options will vest in 48 equal monthly installments over the four-year period beginning on January 1, 2020, subject to the reporting person's continued service to the issuer through each such vesting date. The other one-half of the stock options will vest in 48 equal monthly installments over the four-year period beginning on the date, if any, on which the U.S. Food and Drug Administration approves the Issuer's new drug application for Gimoti, subject to the reporting person's continued service to the issuer through each such vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:37 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 168,750 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001209191-19-038036 · doc4.xml · derivative · entry 12 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,750 Underlying: Common Stock · 168,750 shares Expires 2029-02-05 F12 · derivative.exercise_date: The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on June 17, 2019, subject to the reporting person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:37 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 168,750 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001209191-19-038036 · doc4.xml · derivative · entry 11 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,750 Underlying: Common Stock · 168,750 shares Expires 2028-02-06 F12 · derivative.exercise_date: The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on June 17, 2019, subject to the reporting person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:37 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 168,750 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001209191-19-038036 · doc4.xml · derivative · entry 10 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,750 Underlying: Common Stock · 168,750 shares Expires 2017-01-24 F12 · derivative.exercise_date: The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on June 17, 2019, subject to the reporting person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:37 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001209191-19-038036 · doc4.xml · derivative · entry 9 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2026-02-04 F12 · derivative.exercise_date: The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on June 17, 2019, subject to the reporting person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:37 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 53,015 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001209191-19-038036 · doc4.xml · derivative · entry 8 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,015 Underlying: Common Stock · 53,015 shares Expires 2026-02-04 F12 · derivative.exercise_date: The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on June 17, 2019, subject to the reporting person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:37 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 63,750 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001209191-19-038036 · doc4.xml · derivative · entry 7 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,750 Underlying: Common Stock · 63,750 shares Expires 2026-01-27 F12 · derivative.exercise_date: The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on June 17, 2019, subject to the reporting person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:37 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Disposition to issuerStock Option (Right to Buy) · Derivative | 225,000 | Not disclosed Strike: $2.94 | Not disclosed |
DisclosureSEC source: 0001209191-19-038036 · doc4.xml · derivative · entry 6 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2029-02-05 F11 · price: On June 17, 2019, the Issuer canceled an option granted on February 6, 2019. In exchange for the canceled option, the reporting person received 168,750 options to purchase common stock. F10 · derivative.exercise_date: The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2019, subject to the reporting person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:37 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Disposition to issuerStock Option (Right to Buy) · Derivative | 225,000 | Not disclosed Strike: $2.43 | Not disclosed |
DisclosureSEC source: 0001209191-19-038036 · doc4.xml · derivative · entry 5 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2028-02-06 F9 · price: On June 17, 2019, the Issuer canceled an option granted on February 7, 2018. In exchange for the canceled option, the reporting person received 168,750 options to purchase common stock. F8 · derivative.exercise_date: The option grant date was February 7, 2018, subject to approval of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "Plan") by the Issuer's stockholders which occurred at the Issuer's annual stockholder meeting on April 26, 2018. The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2018, subject to the reporting person's continued service to the Issuer through each such vesting date. Notwithstanding the foregoing vesting schedule, in no event may the option be exercised prior to the earlier of (i) the date on which the Issuer receives marketing approval from the U.S. Food and Drug Administration of Gimoti, (ii) the second anniversary of the date of grant, or (iii) the date of a "change in control" under Section 2.9 of the Plan. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:37 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Disposition to issuerStock Option (Right to Buy) · Derivative | 225,000 | Not disclosed Strike: $2.36 | Not disclosed |
DisclosureSEC source: 0001209191-19-038036 · doc4.xml · derivative · entry 4 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2027-01-24 F7 · price: On June 17, 2019, the Issuer canceled an option granted on January 25, 2017. In exchange for the canceled option, the reporting person received 168,750 options to purchase common stock. F6 · derivative.exercise_date: The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2017, subject to the reporting person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:37 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Disposition to issuerStock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $3.04 | Not disclosed |
DisclosureSEC source: 0001209191-19-038036 · doc4.xml · derivative · entry 3 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2026-02-04 F5 · price: On June 17, 2019, the Issuer canceled an option granted on February 5, 2016. In exchange for the canceled option, the reporting person received 45,000 options to purchase common stock. F3 · derivative.exercise_date: The total number of shares of common stock subject to the option vests in 36 equal monthly installments over the three-year period beginning on January 1, 2016, subject to the reporting person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:37 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,687 | Not disclosed Strike: $3.04 | Not disclosed |
DisclosureSEC source: 0001209191-19-038036 · doc4.xml · derivative · entry 2 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,687 shares Expires 2026-02-04 F4 · price: On June 17, 2019, the Issuer canceled an option granted on February 5, 2016. In exchange for the canceled option, the reporting person received 53,015 options to purchase common stock. F3 · derivative.exercise_date: The total number of shares of common stock subject to the option vests in 36 equal monthly installments over the three-year period beginning on January 1, 2016, subject to the reporting person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:37 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Disposition to issuerStock Option (Right to Buy) · Derivative | 85,000 | Not disclosed Strike: $3.07 | Not disclosed |
DisclosureSEC source: 0001209191-19-038036 · doc4.xml · derivative · entry 1 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,000 shares Expires 2026-01-27 F2 · price: On June 17, 2019, the Issuer canceled an option granted on January 28, 2016. In exchange for the canceled option, the reporting person received 63,750 options to purchase common stock. F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2016, subject to the reporting person's continued service to the Issuer through each such vesting date. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:03 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001209191-19-008467 · doc4.xml · derivative · entry 1 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2029-02-05 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2019, subject to the reporting person's continued service to the Issuer through each such vesting date. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 10:17 UTC | Evoke Pharma Inc EVOK · Entity 71094 | OtherCommon Stock | 6,901 | $1.63 | $11,248.63 |
DisclosureSEC source: 0001209191-18-049421 · doc4.xml · nonDerivative · entry 1 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,544 F1 · kind: These shares were purchased under the Issuer's Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(c). Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 16:16 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001209191-18-026555 · doc4.xml · derivative · entry 1 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2028-02-06 F1 · derivative.exercise_date: The option grant date was February 7, 2018, subject to approval of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "Plan") by the Issuer's stockholders which occurred at the Issuer's annual stockholder meeting on April 26, 2018. The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2018, subject to the reporting person's continued service to the Issuer through each such vesting date. Notwithstanding the foregoing vesting schedule, in no event may the option be exercised prior to the earlier of (i) the date on which the Issuer receives marketing approval from the U.S. Food and Drug Administration of Gimoti, (ii) the second anniversary of the date of grant, or (iii) the date of a "change in control" under Section 2.9 of the Plan. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:38 UTC | Evoke Pharma Inc EVOK · Entity 71094 | OtherCommon Stock | 8,240 | $2.15 | $17,716.00 |
DisclosureSEC source: 0001209191-17-051339 · doc4.xml · nonDerivative · entry 1 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,643 F1 · kind: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(c). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 06:41 UTC | Evoke Pharma Inc EVOK · Entity 71094 | OtherCommon Stock | 12,000 | $1.60 | $19,200.00 |
DisclosureSEC source: 0001209191-17-016247 · doc4.xml · nonDerivative · entry 1 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,403 F1 · kind: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(c). Read SEC document |
| February 08, 2017 Filed Feb 8, 2017 20:50 UTC | Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,200 | $0.00 Strike: $7.65 | $0.00 |
DisclosureSEC source: 0000899243-17-003211 · doc4.xml · derivative · entry 2 Gonyer David A · CIK 0001578768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,200 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On November 4, 2016, the issuer effected a one-for-15 reverse split of its Common Stock (the "Reverse Split"), and the number of securities and/or the exercise price reported reflect the Reverse Split. F1 · shares: On November 4, 2016, the issuer effected a one-for-15 reverse split of its Common Stock (the "Reverse Split"), and the number of securities and/or the exercise price reported reflect the Reverse Split. F2 · derivative.exercise_date: The option initially vested and became exercisable in twelve equal monthly installments beginning on June 30, 2016 and ending on May 31, 2017. However, upon approval of the issuer's board of directors, vesting was accelerated and the option became fully vested. F1 · derivative.underlying_shares: On November 4, 2016, the issuer effected a one-for-15 reverse split of its Common Stock (the "Reverse Split"), and the number of securities and/or the exercise price reported reflect the Reverse Split. Read SEC document |
| February 08, 2017 Filed Feb 8, 2017 20:50 UTC | Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 | Exercise / conversionCommon Stock | 1,200 | $7.65 | $9,180.00 |
DisclosureSEC source: 0000899243-17-003211 · doc4.xml · nonDerivative · entry 1 Gonyer David A · CIK 0001578768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On November 4, 2016, the issuer effected a one-for-15 reverse split of its Common Stock (the "Reverse Split"), and the number of securities and/or the exercise price reported reflect the Reverse Split. F1 · price: On November 4, 2016, the issuer effected a one-for-15 reverse split of its Common Stock (the "Reverse Split"), and the number of securities and/or the exercise price reported reflect the Reverse Split. F1 · balance_after: On November 4, 2016, the issuer effected a one-for-15 reverse split of its Common Stock (the "Reverse Split"), and the number of securities and/or the exercise price reported reflect the Reverse Split. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 17:58 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001209191-17-005985 · doc4.xml · derivative · entry 1 Gonyer David A · CIK 0001578768 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2027-01-24 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2017, subject to the reporting person's continued service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.